Article

Co-promotion agreement covers aflibercept in Japan

Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin Ltd., and Santen Pharmaceutical Co. Ltd. have entered into a co-promotion agreement for aflibercept injection (Eylea, also known as VEGF Trap-Eye; Regeneron Pharmaceuticals) in Japan.

Tarrytown, NY-Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin Ltd., and Santen Pharmaceutical Co. Ltd. have entered into a co-promotion agreement for aflibercept injection (Eylea, also known as VEGF Trap-Eye; Regeneron Pharmaceuticals) in Japan.

In June 2011, Bayer Yakuhin submitted an application for marketing authorization to the Ministry of Health, Labor, and Welfare for aflibercept for the treatment of neovascular age-related macular degeneration (AMD).

Bayer HealthCare and Regeneron are collaborating on the global development of aflibercept, which was approved in the United States for the treatment of wet AMD in November. Regeneron maintains exclusive rights to aflibercept in the United States. Bayer HealthCare owns the exclusive marketing rights outside the United States. Bayer and Regeneron amended their existing global license and collaboration agreement for aflibercept to convert the 50/50 profit share for Japan into a royalty arrangement that approximates the economics of the profit split.

“With this agreement and upon marketing authorization, a newly formed Bayer Yakuhin ophthalmology field force and Santen, the leading ophthalmology company in Japan, will promote [aflibercept],” said Sebastian Guth, president and chief executive officer of Bayer Yakuhin, Ltd. “We expect that the combined resources of the two companies will allow [aflibercept] to achieve a broader and faster reach into the Japanese ophthalmology community and potentially benefit a greater number of patients.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.